Skip to main content
2025 DC/CSEM Professional Conference Main banner

Pedro Geraldes, PhD

Professor
Université de Sherbrooke
Université de Sherbrooke
Sherbrooke, Quebec, Canada

Prof. Pedro Geraldes is a professor in the Department of Medicine, Division of Endocrinology at the Université de Sherbrooke since 2010. He is the director of the Research Center of Excellence of the Université de Sherbrooke and the Research Axe of the Research Center of the Centre Hospitalié Universitaire de Sherbrooke (CRCHUS) in Diabetes, Obesity and Cardiovascular Complications.

Prof. Pedro Geraldes received his Ph.D. in 2006 from the University of Montreal under the supervision of Dr. Jean-François Tanguay investigating the impact of local estrogen treatment on vascular injury processes. Following his PhD program, he joined Dr. George King’s laboratory at Joslin Diabetes Center/Harvard Medical School in Boston where he pursued his career in understanding the role of glucose toxic metabolites on vascular complications of diabetes including the retina and the kidney.

Prof. Pedro Geraldes received several awards and salary support from the ‘Fonds de Recherche du Québec – Santé’ (FRQ-S), Diabetes Canada (New Investigator Award) and CardioMetabolic, Diabetes and Obesity Network (Jean-Davignon Award). He also held a Canada Research Chair in Diabetes and Vascular Complications (Tier 2). During his career, Pr. Geraldes published 46 manuscripts in scientific journals such as Nature Medicine, Cell Metabolism, Diabetes, Circulation Research, Cardiovasc Res, ATVB, and Kidney International.

Prof. Pedro Geraldes’s research investigates how diabetes deregulates protecting factors associated with vascular complications of diabetes such as diabetic kidney disease, peripheral artery disease, wound healing, and atherosclerosis. His group has identified SHP-1, a protein tyrosine phosphatase, to be upregulated by diabetes, which leads to the deactivation of important factors such as insulin, nephrin, podocin, VEGF, and PDGF in vascular cells. His projects are funded by grants from the Canadian Institutes of Health Research, Canada Foundation for Innovation, Kidney Foundation of Canada, Diabetes Canada, Fondation Diabète Brome Missisquoi, and Diabetes Estrie.

Disclosure(s): I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Presentation(s):